Evidence map›Paper›PMID 41078080›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study.

Gbolahan Ajibola, Bryan S Nelson, Aischa Niesar, Seohyun Hong, Melanie Lancien, Molly Pretorius Holme, Michael D Hughes, Dwight E Yin, Patrick Jean-Philippe, Sikhulile Moyo and 9 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03707977 (A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03707977 phase1 / phase2completednot on this map

A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2021Enrolled30ConditionsHIV InfectionArmsART, VRC01LS, 10-1074
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gbolahan AjibolaBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0000-0002-5408-4823
Bryan S NelsonDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0002-4964-067X
Aischa NiesarRagon Institute of Massachusetts General Hospital, MIT, and Harvard, Cambridge, Massachusetts, USA.
Seohyun HongRagon Institute of Massachusetts General Hospital, MIT, and Harvard, Cambridge, Massachusetts, USA.
Melanie LancienRagon Institute of Massachusetts General Hospital, MIT, and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0003-3777-0271
Molly Pretorius HolmeDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0001-5363-2376
Michael D HughesDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Dwight E YinDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-8599-1004
Patrick Jean-PhilippeDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sikhulile MoyoBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0000-0003-3821-4592
Oganne BatlangBotswana Harvard Health Partnership, Gaborone, Botswana.
Maureen SakoiBotswana Harvard Health Partnership, Gaborone, Botswana.
Comfort MaphorisaBotswana Harvard Health Partnership, Gaborone, Botswana.
Terence MohammedBotswana Harvard Health Partnership, Gaborone, Botswana.
Shahin LockmanBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0000-0002-5384-9716
Joseph MakhemaBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0000-0003-0017-2438
Daniel R KuritzkesBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mathias LichterfeldRagon Institute of Massachusetts General Hospital, MIT, and Harvard, Cambridge, Massachusetts, USA.
Roger L ShapiroBotswana Harvard Health Partnership, Gaborone, Botswana.

Funding

Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
Expansion of research and mentoring to improve birth outcomes and treatment outcomes among HIV-affected children in BotswanaK24AI131924 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Roger L Shapiro · 2018 to 2026
$1.6M
Viral Diversity an Innovative Biomarker for Refining Estimates of HIV IncidenceK43TW012350 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI Sikhulile Moyo · 2022 to 2026
$682k
FIC NIH HHS K43 TW012350NIAID NIH HHS K24 AI131924NIAID NIH HHS K24 AI131928
6 · The paper itself

Abstract

backgroundBroadly neutralizing antibodies (bNAbs) are a promising treatment option for children with HIV-1, but their long-term impact on virologic, immunologic, and clinical outcomes is unknown.

methodsThe Tatelo Study investigated dual bNAbs as an alternative to standard antiretroviral treatment (ART) in children. Children received bNAb-only treatment for 24 weeks (or until detectable viremia ≥400 copies/mL occurred) and were followed initially through 24 weeks after restarting ART. We continued follow-up from 24 to 96 weeks post-bNAb intervention to identify the long-term clinical, immunologic, and viral reservoir outcomes.

resultsMedian age at the start of long-term follow-up was 4.9 years (range 3.4, 6.8 years). From 23.0 to 43.6 weeks post-bNAb intervention, all 25 children transitioned to dolutegravir-based ART; 3 (12%) had a single episode of HIV-1 RNA ≥ 40 copies/mL after starting the DTG-based regimen and re-suppressed with adherence counseling on the same regimen. There were no grade 3 or 4 events, and no child died. Absolute CD4 cell counts remained stable at 96 weeks post-bNAb intervention (median: 1130 cells/mm3, IQR: 840, 1249 cells/mm3), and clinical biomarkers (serology, qualitative HIV DNA) were stable. At last available sampling, only 8 (32%) participants had detectable intact provirus (5 had rebounded during the bNAb-only intervention phase), with a low median HIV-1 DNA in PBMCs of 0.39 log10 (range 0.1 to 3.8 log10) copies/106 cells.

conclusionsThere was no long-term impact on safety, clinical, immunologic, or virologic outcomes after bNAb-only treatment, including for children who rebounded during the intervention. These findings support further bNAb treatment trials in children. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov, NCT03707977, https://clinicaltrials.gov/.

Indexed as

Botswanabroadly neutralizing antibodiesHIVpediatrictreatment

Identifiers

PMID41078080
PMCPMC13017575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.